# Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026
Canonical URL: https://biopharmsignal.com/news/STIM/neuronetics-highlights-continued-advancements-in-tms-research-at-ctmss-2026
Ticker: STIM
Company: Neuronetics
Source: Neuronetics
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.neuronetics.com
## Summary

New findings from the industry’s largest real-world TMS database reinforce NeuroStar’s leadership in advancing evidence-based mental health care MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and

## Article Body
New findings from the industry’s largest real-world TMS database reinforce NeuroStar’s leadership in advancing evidence-based mental health care MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and
## Recent Company News
- 2026-07-06 12:30 EST — [Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026](https://biopharmsignal.com/news/STIM/neuronetics-to-participate-in-a-panel-discussion-at-b-riley-securities-mind-musc-e3db286d) — Source: Neuronetics
- 2026-06-25 13:46 EST — [Neuronetics Appoints Robert Greene as Senior Vice President Sales](https://biopharmsignal.com/news/STIM/neuronetics-appoints-robert-greene-as-senior-vice-president-sales) — Source: Neuronetics
- 2026-06-25 13:46 EST — [Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026](https://biopharmsignal.com/news/STIM/neuronetics-highlights-continued-advancements-in-tms-research-at-ctmss-2026) — Source: Neuronetics
- 2026-06-25 13:46 EST — [Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment](https://biopharmsignal.com/news/STIM/neuronetics-and-ant-neuro-announce-strategic-collaboration-to-integrate-neuronavigation-with-neurostar-tms-treatment) — Source: Neuronetics
- 2026-06-25 13:46 EST — [Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results](https://biopharmsignal.com/news/STIM/neuronetics-announces-selected-preliminary-unaudited-fourth-quarter-and-full-year-2025-financial-results) — Source: Neuronetics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)